{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:09:51Z","timestamp":1716552591229},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ygyno.2011.12.417","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T05:51:26Z","timestamp":1323669086000},"page":"54-58","source":"Crossref","is-referenced-by-count":8,"title":["A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"125","author":[{"given":"Natalie","family":"Gould","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Diane","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lari","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.12.417_bb0010","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/gyno.1994.1005","article-title":"A Phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients","volume":"52","author":"M\u00e4lmstrom","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1993.1171","article-title":"Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer","volume":"50","author":"Markman","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.12.005","article-title":"Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer","volume":"97","author":"Fujiwara","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-NTX subscale for platinum\/paclitaxel-induced neurologic symptoms: a Gynecologic Oncology Group study","volume":"17","author":"Huang","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2011.12.417_bb0055","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/oxfordjournals.annonc.a010672","article-title":"Workshop on phase I design: Ninth NCI EORTC new drug development symposium, Amsterdam, March 12, 1996","volume":"7","author":"Arbuck","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedures for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/2529393","article-title":"Multiple-stage procedures for drug screening","volume":"29","author":"Schultz","year":"1973","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0070","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2009.01.007","article-title":"Intraperitoneal chemotherapy for ovarian cancer: 2009 goals","volume":"112","author":"Walker","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Miyagi","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0080","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1525-1438.2005.15304.x","article-title":"Preliminary toxicity analysis of intraperitoneal ( IP) carboplatin in combination with intravenous (IV) paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube","volume":"15","author":"Fujiwara","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2010.12.358","article-title":"A Phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube and primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"121","author":"Morgan","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.417_bb0095","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1200\/JCO.2007.11.7275","article-title":"Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions","volume":"25","author":"Wagner","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811013904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811013904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T23:24:46Z","timestamp":1543361086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811013904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0090825811013904"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.12.417","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}